Ajanta Pharma on Monday said its consolidated profit after tax increased 4% year-on-year to Rs 255 crore in the first quarter ended June 30, 2025, aided by robust sales of branded generics. The Mumbai-based drug maker reported a profit after tax of Rs 246 crore in the June quarter of the last fiscal.
Revenue from operations rose to Rs 1,303 crore in the period under review as compared with Rs 1,145 crore in the year-ago period, Ajanta Pharma said in a regulatory filing.
The company's sales of branded generics in India, Asia and Africa climbed by 9% year-on-year to Rs 941 crore in the April-June quarter this fiscal.
Sales of generics in the US market stood at Rs 310 crore in the June quarter, a growth of 36% year-on-year, as against Rs 228 crore in the same period last year.
Shares of the company ended 0.99% down at Rs 2,753.65 apiece on the BSE.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
